Gossamer Bio (NASDAQ:GOSS) Now Covered by Analysts at Scotiabank

Scotiabank initiated coverage on shares of Gossamer Bio (NASDAQ:GOSS - Free Report) in a research report released on Monday morning, MarketBeat.com reports. The brokerage issued a sector outperform rating and a $11.00 target price on the stock.

GOSS has been the subject of a number of other research reports. The Goldman Sachs Group boosted their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, May 16th. Wedbush restated an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Friday, May 16th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Gossamer Bio in a research note on Tuesday, March 18th.

Gossamer Bio Stock Performance

Shares of GOSS stock traded up $0.07 during mid-day trading on Monday, reaching $1.73. 2,728,359 shares of the company's stock traded hands, compared to its average volume of 1,453,361. Gossamer Bio has a 12 month low of $0.66 and a 12 month high of $1.73. The firm has a 50 day moving average price of $1.24 and a two-hundred day moving average price of $1.13. The company has a debt-to-equity ratio of 6.70, a quick ratio of 5.71 and a current ratio of 5.71. The firm has a market capitalization of $392.09 million, a PE ratio of -7.50 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. Gossamer Bio had a negative net margin of 41.12% and a negative return on equity of 128.98%. The firm had revenue of $9.89 million during the quarter, compared to the consensus estimate of $3.95 million. On average, research analysts forecast that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio during the 4th quarter valued at $32,000. Virtu Financial LLC bought a new stake in shares of Gossamer Bio in the first quarter worth about $38,000. Fullcircle Wealth LLC bought a new stake in shares of Gossamer Bio in the fourth quarter worth about $43,000. Invesco Ltd. purchased a new stake in shares of Gossamer Bio in the first quarter worth about $48,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Gossamer Bio in the fourth quarter worth about $68,000. Hedge funds and other institutional investors own 81.23% of the company's stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.